Xarelto Lawsuit Plaintiffs Gain Support From Studies Connecting Drug Use To Dangerous Bleeding Episodes

February 29, 2016 – – BloodThinnerHelp.com reports on important results gained from multiple studies which have brought up fresh concerns over the public use of anticoagulant Xarelto by connecting it to sudden and dangerous bleeding episodes in patients. This supports the arguments of many lawsuit plaintiffs who have stepped forward filing lawsuits against Xarelto manufacturers Janssen Pharmaceuticals and Bayer AG, all who similarly allege that the anticoagulant puts users at increased risk for serious and even fatal bleeding side effects.

The U.S. Food and Drug Administration (FDA) approved Xarelto in 2011. It was initially approved to treat patients at increased risk of developing blood clots or having strokes. Additionally, it was intended to be given to individuals recovering from knee and hip replacement surgeries, and those suffering from pulmonary embolism or deep vein thrombosis. Shortly after its initial approval, Xarelto’s approved treatments were expanded to include patients who suffered from atrial fibrillation.

Increasing talks of dangerous side effects linked to Xarelto spurred doctors Judy Hun and John Hwang to further investigate the anticoagulant’s effects on their own patients. They found that within their own practice, they began to notice that some of their patients had developed “spontaneous vitreous hemorrhage” (or sudden eye-bleeding) while using Xarelto. After studying this possible link, the medical team found that risks of these eye bleeding occurrences may be elevated; especially among patients who had transitioned from taking traditional blood thinners to taking Xarelto.

Unfortunately, this study is not the only one to have linked Xarelto use by patients to an increased risk of sudden bleeding episodes. Another study, which ran from October 1, 2010, to March 31, 2012, evaluated thousands of patients from across the U.S. who had taken either Xarelto, Pradaxa, or warfarin blood thinners. While observing a large sample of 46,000 patients, 39,607 of whom used warfarin, 4,907 of whom used Pradaxa, and 1,649 of whom used Xarelto, results showed “as much as a 50% increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin or a more than twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.”

Today, lawsuit numbers filed against Xarelto manufacturers have surpassed 2,800 cases in federal court, and include an additional 550 or more cases which have formed a mass tort group in Philadelphia, Pennsylvania. All federally-filed cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML) to form MDL number 2592 in Eastern Louisiana, and are currently being overseen by Judge Eldon Fallon.

At this time, Attorney Joseph Osborne is working to assist anyone who has taken Xarelto and has also suffered from health problems that they link to the drug. It is believed that these individuals may be entitled to legal action and substantial compensation. Because everyone deserves the important opportunity to explore their legal rights in full, Attorney Osborne is helping to facilitate this process by offering free legal consultations to those affected.

To obtain additional information on Xarelto bleeding lawsuits, or to ask questions, please call Attorney Osborne at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008416